Article

BTK Inhibitors in MCL and CLL

Related Videos
Tycel Phillips, MD, MPH
Pallawi Torka, MD
Carolyn Owen, MD, FRCPC
Alexey V. Danilov, MD, PhD
Kami J. Maddocks, MD
Matthew A. Lunning, DO, FACP
Anita Kumar, MD
Sarah Sammons, MD
Laura Spring, MD
Related Content
An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer
April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Clinical Decision Making in Advanced NSCLC without Actionable Mutations
April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?
January 25th 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer
January 25th 2023

Clinical Case Scenarios: Approaches to Treatment Decisions in Non-Small Cell Lung Cancer

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
December 22nd 2022

Advances in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma